Research presented at the ASCO Annual Meeting 2025 highlighted new potential standards of care and other advances in breast cancer.

Discover which therapies are expected to grab the HER2-low cancers market share @ HER2-low Cancers Market Report The HER2-low ...

In separate, live virtual events, William J. Gradishar, MD; and Tiffany A. Traina, MD, discussed multiple scenarios for a ...

AstraZeneca (NASDAQ:AZN) is one of the 8 Best Inexpensive Stocks to Buy Right Now. On June 9, the first patient was dosed by ...

Abstract: The purpose of this document is to introduce the application of manual tissue microarrays in the production of immunohistochemistry (IHC) positive tissue controls for ALK, P16, HER2, and ...

Artificial intelligence (AI)-assisted training improves pathologist accuracy in human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) scoring in patients with breast cancer.

I maintain a Buy rating on Zymeworks Inc. stock due to platform promise and upcoming catalysts. However, click for why I am ...

HER2 expression has been associated with poor responses to intravesical BCG in patients with high-risk NMIBC, ... (cTa/T1 ± CIS, N0, M0) and HER2 IHC 1+, 2+, or 3+ status. All patients underwent TURBT ...

In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 study for the treatment of patients with HER2-expressing, mismatch repair ...

Expert Rev Mol Diagn. 2008;8(4):417-434. The College of American Pathologists (CAP) and ASCO recently organized an expert panel, which conducted a systematic review of the literature and developed ...

DESTINY-Endometrial01 is a global, multicenter, randomized, open-label phase 3 trial evaluating the efficacy and safety of ENHERTU (5.4 mg/kg) in combination with rilvegostomig or pembrolizumab versus ...